The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression

Pharmacopsychiatry

Volumn 45, Issue 3, 2012, Pages 108-113

  Dreimuller N ^a   Tadi, A ^a   Dragicevic, A ^a   Boland, K ^b   Bondy, B ^c   Lieb, K ^a   Laux, G ^d   Maier, W ^b   Muller M J ^e   Rao, M L ^b   Rietschel, M ^f   Roschke J ^g   Zill, P ^c   Hiemke, C ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Inn Salzach Hospital   (Germany)

^e UNIVERSITY HOSPITAL MARBURG   (Germany)

^f CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^g SCIVIAS St Valentinus Hospital   (Germany)

Author keywords

5 HTTLPR; depression; SSRI; TDM

Indexed keywords

CITALOPRAM; FLUVOXAMINE; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENE LOCUS; GENOTYPE; HUMAN; MAJOR DEPRESSION; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; REMISSION; SEROTONIN TRANSPORTER PROMOTER POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84861228816     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1291347     Document Type: Article

References (40)

1. Trivedi M H, Rush A J, Wisniewski S R. et al., STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement based care in STAR*D: implications for clinical practice. Am J Psychiatry: 2006; 163 28 40 (Pubitemid 43050100)
2. Rush A J, Trivedi M H, Wisniewski S R et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry: 2006; 163 1905 1917 (Pubitemid 44807782)
3. Bauer M, Whybrow P C, Angst J. et al., World Federation of Societies of Biological Psychiatry (WFSBP). Guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry: 2002; 3 5 43
4. Adli M, Baethge C, Heinz A et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci: 2005; 255 387 400 (Pubitemid 43029828)
5. Corruble E, Guelfi J D. Does increasing dose improve efficacy in patients with poor antidepressant response: a review. Acta Psychiatr Scand: 2000; 101 343 348 (Pubitemid 30232998)
6. Benkert O, Szegedi A, Wetzel H et al. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand: 1997; 95 288 296 (Pubitemid 27183452)
7. Dornseif B E, Dunlop S R, Potvin J H et al. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull: 1989; 25 71 79 (Pubitemid 19179164)
8. Schweizer E, Rynn M, Mandos L A et al. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int J Clin Psychopharmacol: 2001; 16 137 143 (Pubitemid 32402358)
9. Licht R W, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology: 2002; 161 143 151 (Pubitemid 34492659)
10. Ostad Haji E, Tadi A, Wagner S et al. Association between citalopram serum levels and clinical improvement of patients with major depression. J Clin Psychopharmacol: 2011; 3 281 286
11. 11C]DASB positron emission tomography study. Am J Psychiatry: 2004; 161 826 835 (Pubitemid 38625335)
12. Kelly M W, Perry P J, Holstad S G et al. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit: 1989; 11 165 170 (Pubitemid 19064841)
13. Preskorn S H. Clinical pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokinetics: 1997; 32 01 1 21
14. Tasker T C, Kaye C M, Zussman B D et al. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Act Psychiatr Scand: 1989; 350 Suppl 152 155 (Pubitemid 19236668)
15. Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996. 66 2621-2624
16. Lesch K P, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science: 1996; 29 1527 1531 (Pubitemid 26403928)
17. Eichhammer P, Langguth B, Wiegand R et al. Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI). Psychopharmacology (Berl): 2006; 66 294 297 (Pubitemid 36384777)
18. Pollock B G, Ferrell R E, Mulsant B H et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology: 2000; 23 587 590
19. Smeraldi E, Zanardi R, Benedetti F et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry: 1998; 3 508 511 (Pubitemid 28515526)
20. Zanardi R, Benedetti F, Di Bella D et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol: 2000; 20 105 107 (Pubitemid 30056365)
21. Zanardi R, Serretti A, Rossini D et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry: 2001; 50 323 330 (Pubitemid 32816944)
22. Kraft J B, Peters E J, Slager S L et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry: 2007; 61 734 742 (Pubitemid 46330243)
23. Durham L K, Webb S M, Milos P M et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl): 2004; 174 525 529 (Pubitemid 39119341)
24. Serretti A, Kato M, De Ronchi D et al. Metaanalysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry: 2007; 12 247 257 (Pubitemid 46328503)
25. Grasmäder K, Lohmann P L, Kuss H J et al. Therapeutisches Drug-Monitoring von Antidepressiva- therapeutischer und gesundheitö konomischer Nutzen. Med Med Monatsschr Pharm: 2003; 26 162 164 (Pubitemid 36596829)
26. Hamilton M. A rating scale for depression. JNNP: 1960; 23 56 61
27. Hu X, Oroszi G, Chun J et al. An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res: 2005; 29 8 16 (Pubitemid 40129206)
28. Frahnert C, Rao M L, Grasmäder K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J Chromatogr B Analyt Technol Biomed Life Sci: 2003; 794 35 47 (Pubitemid 36897624)
29. Greiner C, Hiemke C, Bader W et al. Determination of citalopram and escitalopram together with their active main metabolites desmethyl (es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. J Chromatogr B: 2007; 848 391 394 (Pubitemid 46453308)
30. Baumann P, Hiemke C, Ulrich S et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry: 2004; 37 243 265 (Pubitemid 39587052)
31. Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit: 2000; 22 446 454 (Pubitemid 30622118)
32. Härtter S, Wetzel H, Hammes E et al. Serum concentrations of fluvoxamine and clinical effects. Pharmacopsychiatry: 1998; 31 199 200
33. Lundmark J, Reis M, Bengtsson F. Serum concentrations of fluoxetine in the clinical treatment setting. Ther Drug Monit: 2001; 23 139 147 (Pubitemid 32240141)
34. Lundmark J, Bengtsson F, Nordin C et al. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand: 2000; 101 354 359 (Pubitemid 30233000)
35. Ruh H G, Booij J, Weert H C et al. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology: 2009; 34 999 1010
36. Müller M J, Dragicevic A. Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices. J Affect Disord: 2003; 77 65 69 (Pubitemid 37205152)
37. 11C]DASB positron emission tomography. Psychopharmacology (Berl): 2007; 193 539 545 (Pubitemid 47094376)
38. Ruh H G, Ooteman W, Booij J et al. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet Genomics: 2009; 1 67 76
39. 11C]-DASB binding in the living human brain. Neuroimage: 2010; 52 50 54
40. Tanum L, Strand L P, Refsum H. Serum concentrations of citalopram dose-dependent variation in R- and S-entantiomer ratios. Pharmacopsychiatry: 2010; 43 190 193